viewAntibe Therapeutics Inc

Antibe Therapeutics sees article highlighting its anti-inflammatory drug published in medical journal

The piece covers a series of studies of ATB-352, which treats pain by releasing hydrogen sulfide

Person with scrubs and a stethoscope reading a tablet
ATB-352 is a derivative of the NSAID ketoprofen but studies showed it induced greater pain relief

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) announced Monday that an article showcasing the benefits of its anti-inflammatory drug candidate has been published in a medical journal.  

The piece, which appeared in the publication “Antioxidant and Redox Signaling,” reported on a series of studies of ATB-352, the company’s derivative of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen. 

The studies show that ATB-352 induces greater pain relief than ketoprofen in a well-characterized animal model of surgical pain.

READ: Antibe Therapeutics bolsters executive team in preparation for ATB-346 commercialization

In addition to blocking the production of pain-promoting substances called “prostaglandins”, the company said, ATB-352 further reduced pain by elevating levels of naturally-occurring endocannabinoids in comparison to the levels of endocannabinoids observed in mice treated with ketoprofen.

Like ketoprofen, ATB-352 treats pain by releasing hydrogen sulfide, but Antibe’s alternative is being developed to also avoid some of its side effects, namely damage to the gastrointestinal tract.  

The studies were led by Antibe Chief Science Officer John Wallace and featured researchers from the University of Calgary in Canada; the University of Sao Paulo and the University of Campinas in Brazil; and Umea University in Sweden.

The journal article is titled, “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti- Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids.”

Toronto-based Antibe is also working to develop and commercialize its lead drug, ATB-346, which targets acute and chronic pain associated with osteoarthritis.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Antibe Therapeutics Inc

Price: 0.77 CAD

Market: TSX-V
Market Cap: $216.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...



Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

on 7/4/20

2 min read